dulaglutide
Sign in to saveDulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Key facts
- Drug.image
- Autoinjector with Trulicity by Lilly (Dulaglutid)-3129.jpg
- Drug.alt
- Autoinjector with Trulicity by Lilly
- Drug.tradename
- Trulicity, others
- Drug.MedlinePlus
- a614047
- Drug.DailyMedID
- Dulaglutide
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Subcutaneous
- Drug.class
- Incretin mimetics
- Drug.ATC_prefix
- A10
- Drug.ATC_suffix
- BJ05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 923950-08-7
- Drug.IUPHAR_ligand
- 7638
- Drug.DrugBank
- DB09045
- Drug.UNII
- WTT295HSY5
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2014
- Admin. routes
- parenteral
- Indications
- smoking cessation, diabetes mellitus, Polydipsia, chronic kidney disease
via ChEMBL · EBI
Research
1,253 papers- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet (London, England) · 2019
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.The lancet. Diabetes & endocrinology · 2018
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.American heart journal · 2024
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.The lancet. Diabetes & endocrinology · 2022
via PubMed
Wikidata facts
- Subclass of
- fusion protein
- Has use
- medication
Show 7 more facts
- subject has role
- anti-diabetic medication
- medical condition treated
- glucose intolerance
- World Health Organisation international non-proprietary name
- dulaglutide
- Commons category
- Dulaglutide
- defined daily dose
- 0.16
- has characteristic
- biopharmaceutical
- legal status (medicine)
- boxed warning
Sources (7)
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Side effects
- Contraindications
- Mechanism of action
- History
- See also
- References
- Further reading
Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
Excerpted from Wikipedia’s “dulaglutide” article, available under the CC BY-SA 4.0 licence.